Mylan launches generic Seasonique

PITTSBURGH — Mylan announced on Tuesday that it had launched its generic version of Teva’s Seasonique birth control (Levonorgestrel and Ethinyl Estradiol Tablets USP, 0.15 mg/0.03 mg and Ethinyl Estradiol Tablets USP, 0.01 mg). The medication saw some $160.7 million in sales in the 12 months that ended on March 31 of this year. 

 

The launch follows the Food and Drug Administration’s approval of Mylan partner Famy Care’s abbreviated new drug application for the drug. Mylan has 271 ANDAs still awaiting FDA approvals, 47 of which are first-to-file opportunities.